Jacobs Levy Equity Management Inc. Boosts Stock Holdings in Astrana Health, Inc. $ASTH

Jacobs Levy Equity Management Inc. lifted its holdings in Astrana Health, Inc. (NASDAQ:ASTH - Free Report) by 211.6% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 237,926 shares of the company's stock after acquiring an additional 161,580 shares during the period. Jacobs Levy Equity Management Inc. owned approximately 0.42% of Astrana Health worth $7,378,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently made changes to their positions in ASTH. Covestor Ltd raised its position in shares of Astrana Health by 777.6% in the 1st quarter. Covestor Ltd now owns 2,001 shares of the company's stock worth $62,000 after acquiring an additional 1,773 shares in the last quarter. AlphaQuest LLC raised its position in shares of Astrana Health by 144.2% in the 1st quarter. AlphaQuest LLC now owns 4,883 shares of the company's stock worth $151,000 after acquiring an additional 2,883 shares in the last quarter. US Bancorp DE raised its position in shares of Astrana Health by 21.3% in the 1st quarter. US Bancorp DE now owns 5,791 shares of the company's stock worth $180,000 after acquiring an additional 1,015 shares in the last quarter. Hsbc Holdings PLC bought a new position in shares of Astrana Health in the 1st quarter worth about $200,000. Finally, PharVision Advisers LLC acquired a new stake in shares of Astrana Health in the 4th quarter valued at about $211,000. 52.77% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, Zacks Research downgraded Astrana Health from a "strong-buy" rating to a "strong sell" rating in a research note on Monday, September 1st. Six research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, Astrana Health has a consensus rating of "Moderate Buy" and an average target price of $53.29.

Astrana Health Stock Down 1.8%

ASTH stock traded down $0.55 during mid-day trading on Friday, reaching $29.83. 214,877 shares of the company traded hands, compared to its average volume of 339,233. Astrana Health, Inc. has a fifty-two week low of $21.20 and a fifty-two week high of $63.20. The firm's 50 day moving average price is $26.96 and its 200 day moving average price is $27.93. The stock has a market cap of $1.67 billion, a price-to-earnings ratio of 58.49, a P/E/G ratio of 0.75 and a beta of 0.85. The company has a quick ratio of 1.59, a current ratio of 1.59 and a debt-to-equity ratio of 0.52.

Astrana Health (NASDAQ:ASTH - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $0.19 earnings per share for the quarter, missing analysts' consensus estimates of $0.36 by ($0.17). Astrana Health had a return on equity of 3.43% and a net margin of 1.04%.The business had revenue of $654.81 million during the quarter, compared to analysts' expectations of $639.13 million. During the same quarter in the previous year, the firm earned $0.40 EPS. Astrana Health's quarterly revenue was up 34.7% on a year-over-year basis. Astrana Health has set its Q3 2025 guidance at EPS. As a group, equities research analysts predict that Astrana Health, Inc. will post 1.15 EPS for the current fiscal year.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.